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Scanning alanine mutagenesis has been used to study the structural determinants of several activities of bothropstoxin-I (BthTx-I), a lysine 49
Phospholipases A2 from the venom of Bothrops jararacussu. A total of 31 mutants were generated in the interfacial recognition site and C-
terminal loop regions of the protein. The effects of mutagenesis on the in vivo myotoxic activity, the cytolytic activity against cultured C2C12
myoblasts, the bactericidal activity, and the Ca2+-independent membrane damaging activity against liposome membranes were compared.
Residues 116–119 and 122–125 in the C-terminal loop region are structural determinants for these activities, indicating that membrane
permeabilization by the BthTx-I is an important general property in all the measured effects. The structural determinants of myotoxicity and
myoblast membrane permeabilization are highly correlated, demonstrating that cultured C2C12 myoblasts are a good model for the myotoxic
effect. However, comparison of the structural determinants for all activities revealed several differences in the structural determinants between the
effects against myoblast and bacterial membranes, and further differences when compared to the liposome membrane damaging effect. These
membrane dependent effects are interpreted to be the consequence of differences in the activation of the membrane bound form of the protein on
biological and artificial membranes.
© 2007 Elsevier B.V. All rights reserved.Keywords: Bothropstoxin-I; Myotoxin; Bactericide; Myoblast; Liposome; PLA21. Introduction
Phospholipases A2 (PLA2-EC 3.1.1.4) catalyze the hydro-
lysis the sn-2 acyl bonds of sn-3 phospholipids [1], and are
currently classified in 15 groups on the basis of disulphide
bonding patterns and amino acid sequence similarity [2]. The
hydrolysis of phospholipids by Group I/II PLA2s involves a
His48/Asp99 pair in the catalytic site that activate a conserved
water molecule, thereby initiating the nucleophilic attack on the
sn-2 position of the substrate [3,4]. Many snake venom PLA2s⁎ Corresponding author. Tel.: +55 16 36024384; fax: +55 16 36024838.
E-mail address: rjward@ffclrp.usp.br (R.J. Ward).
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doi:10.1016/j.bbamem.2007.01.023(vPLA2) present pharmacological properties [5], and it is well
documented that at least some of these activities are mediated
by interactions between the vPLA2 and a specific receptor or
acceptor on the target cell membrane [6–10]. Although the
details of the mechanisms through which the venom PLA2s
exert these effects is not fully understood, the evidence suggests
that the catalytic function is not necessary in the case of some of
these pharmacological effects [11–16].
Catalytically inactive vPLA2s have been described that
present a high degree of amino acid sequence similarity to other
group II PLA2s. In these PLA2 variants, the aspartic acid residue
at position 49 (Asp49) that is invariable in catalytically active
PLA2s, is substituted by a lysine residue (Lys49). Since their
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PLA2s from 23 crotalid and viperid snake venoms have been
deposited in the public sequence databases. Comparison of the
crystal structures of Lys49–PLA2s demonstrates that the
ε-amino group of the Lys49 is located in the position normally
occupied by the Ca2+ cofactor in the Asp49-PLA2 [17–19], and
it has been suggested that the Lys49–PLA2s are catalytically
inactive as a consequence of the loss Ca2+ cofactor binding.
Although the Lys49–PLA2s do not show catalytic activity,
interaction with liposome membranes results in the rapid
liberation of the liposome contents via a Ca2+-independent
mechanism that does not involve the hydrolysis of membrane
phospholipids [20–22]. Nevertheless, the in vivo activities of
the Lys49–PLA2s include the formation of edema and local
myonecrosis [23,24], cytoloysis of a wide range of cell types
[14,25], bactericidal activity [15,26] and local inflammation and
pain [11,12,27,28].
Based on a visual analyses of PLA2 myotoxin sequence
alignments, it has been suggested that either an extended surface
including polar and cationic residues primarily on helix 3 [29]
or that residues 78 to 87 located in the β-wing region of the
PLA2s [30] are determinants of the myotoxic effect. More
refined methods for analysis of multiple amino acid sequence
alignments have been developed which identify the specific
amino acid residues that define sub-groups of proteins [31–33].
When applied to Lys49–PLA2s sequences this analysis yielded
a list of 12 specific residues that were mapped to 3 amino acid
clusters located in the active site region, the hydrophobic fatty
acyl chain binding pocket and the tip of the β-wing [34].
Subsequent site-directed mutagenesis results using both-
ropstoxin-I, a Lys49–PLA2 from the venom of Bothrops
jararacussu, have confirmed that all these three regions play
important and distinct roles in the Ca2+-independent membrane
damaging mechanism [35–37].
A method for comparing residue variability in highly similar
amino acid sequences has identified positions in the C-terminal
loop region of the Lys49–PLA2 myotoxins , which were not
identified using previously available sequence analysis tools
[5], and were identified as candidates for being the structural
determinants of the biological effects of Lys49–PLA2 myotox-
ins. This prediction is supported by the observation that a
synthetic peptide of residues 115–129 in the C-terminal region
of the myotoxin-II from Bothrops asper demonstrates biological
activity, although at reduced levels when compared to the intact
protein [25]. Furthermore, this prediction shows a good
correlation with previous results of site directed mutagenesis
experiments in BthTx-I, which demonstrated that positions 117
to 122 influence the myotoxic activity in the C-terminal loop
region [38]. Here we have extended these studies to further
elucidate the structural determinants of the pharmacological
activities of the Lys49–PLA2s, and to understand the role of the
Ca2+-independent membrane damaging activity in these effects.
In group I/II PLA2s, the interfacial recognition site (IRS,
[39]) or the i-face [40] is a region of the protein defined by a
highly conserved hydrophobic surface cleft that binds the fatty
acyl chain of the phospholipid substrate, together with a
surrounding ring of more variable polar and charged residues.This report presents the result of the effects of a scanning
alanine mutagenesis study of all cationic residues in the IRS and
all residues around the C-terminal loop region of the BthTx-I.
The effects of a total of 31 mutants on the myotoxicity,
membrane permeabilization of cultured C2C12 myoblasts,
bactericidal activity and liposome membrane disruption have
been evaluated and compared with previous site-directed
mutagenesis studies of the BthTx-I.
2. Materials and methods
2.1. Protein purification from crude venom
Bothropstoxin-I (BthTx-I) was purified from crude lyophilized B.
jararacussu venom using single step cation-exchange chromatography as
previously described [37]. The BthTx-I eluted as a single peak and was dialyzed
against 5 mM Tris–HCl, pH 7.5 for 36 h with buffer changes every 12 h and
concentrated 10-fold by lyophilization. Protein purity was routinely evaluated
by silver staining of SDS-PAGE gels [41], and aliquots of purified protein were
stored at 4 °C until further use.
2.2. Site directed mutagenesis
A full-length cDNA encoding BthTx-I has been previously isolated from B.
jararacussu venom gland cDNA by RT-PCR (GenBank Acc. No. X78599) [42],
and sub-cloned into the expression vector pET3-d [43]. Nucleotide sequencing
has confirmed the construct in which Ser1 of the BthTx-I is preceded by a Met,
and a stop codon immediately follows Cys133 (homology numbering as
reported previously [44] is used throughout this report). After linearization of
this construct with ScaI, site directed mutagenesis of the BthTx-I was performed
by PCR mutagenesis [45] to introduce a total of 31 single mutations (shown in
Table 1). The final PCR reactions were performed using oligonucleotides
complementary to the vector sequences flanking the BthTx-I insert which
contained restriction sites for XbaI (5′-extremity) and BamHI (3′-extremity).
After digestion with these enzymes, the amplified fragments were subcloned
into the equivalent sites in the expression vector pET3d and fully sequenced.
2.3. Recombinant protein expression and purification
Four hundred millilitres of growth medium (per litre, 25 g yeast extract; 15 g
tryptone; 10 mMolMgSO4; 35 mg chloramphenicol; 100 mg ampicillin; pH 7.5)
was inoculated with Escherichia coli strain BL21(DE3){pLysS} transformed
with the native or mutant constructs in pET3d, and grown at 37 °C to an A600 of
0.6. Recombinant protein expression was induced by addition of 0.6 mM IPTG,
and the culture grown for an additional 7 h. Inclusion bodies were isolated from
bacterial pellets by repeated rounds of sonication in 20 mL of lysis buffer
(50 mM Tris–HCl, pH 8.0; 1 mM EDTA; 0.4 M urea; 1% Triton X-100)
followed by centrifugation at 12,000 g. The protocol for the solubilization and
refolding of recombinant BthTx-I in the presence of a gel filtration medium was
performed as previously described [43]. The refolded protein was applied
directly to the cation exchange column and eluted as described earlier for the
purification of the native BthTx-I from crude venom.
2.4. Release of entrapped fluorescent markers from liposomes
Membrane damaging activity was evaluated by the release of the liposome
entrapped self-quenching fluorescent dye calcein. The loss of liposome
membrane integrity results in dilution of the fluorophore with a consequent
increase in the fluorescence signal [21,22]. Unilamellar liposomes composed of
either mixtures of egg yolk phosphatidylcholine (EYPC):dimyristroyl phos-
phatidic acid (DMPA) or EYPC: egg yolk phosphatidylglycerol (EYPG) at a 9:1
molar ratio containing 25 mM calcein (Sigma) were prepared by reverse phase
evaporation as described previously [22], and mixed with BthTx-I to a final
protein:lipid molar ratio of 1:400. Membrane damage kinetics were monitored
by the increase in fluorescence emission at 520 nm with excitation at 490 nm,
Table 1
Oligonucleotide sequences of primers used for the site-directed mutagenesis
experiments
Mutant Oligonucleotide sequence
K7A GCAGGATCATTGCCCCGAGCTC
K15A AGCAGGGTTTGCCCCCGTCTC
K36A CCTTTGGCGCGCCTCGGCC
P37A GGCGTCCTTTGCCTTGCCTCG
K38A GGCGTCCGCTGGCTTGCC 3
D39A CAGTGGCGGCCTTTGGCTT
R43A AGCAGCAGGCGTCAGTGGC
Y46A TTGTGCACGGCGCAGCAGCG
H48Qa GTAACAGCATTTCTGCACGTAGCAGC
K53A CAGTTTTGCGTAACAGCA
K54A CGCAGCCGGTCAGTGCTTTGTAACA
I-K57/R58 GGGGTCGCAGCCTCGTTTGGTCAGTTT
K80A GATAGTCGCGTCCTTCC
E86G TGGGTTGTTCCCTCCGCAG
K93A ACACAACTCTGCCAGGC
K100A TGCCACGGCCGCGTCGCACTC
T112A TTGTTGTACGCGCCCAGATT
N114A ATTTTTTGGCGTACGTGCC
K115Ab CCTATATTTTGCGTTGTACCT
K116Ab ATACCTATATGCTTTGTTGTA
Y117A GATACCTAGCTTTTTTGTT
Y117Wb GTGATACCTCCATTTTTTGTT
R118Ab CAGGTGATACGCATATTTTTT
Y119A TTCACGTGAGCCCTATATTT
Y119Wb TTTCAGGTGCCACCCTATATTT
H120A TTCAGGGCATACCTATA
L121A GCAAAAAGGTTTCGCGTGATACCT
K122Ab GCAAAAAGGTGCCAGGTGATA
F125A TTGCAAGCAGGTTTCAG
F125Wb CTTTTTGCACCAAGGTTTCAG
K129Ab GGCGTCGGCCGCTTTGCAAAA
All sequences are shown in the 5′ to 3′ direction, and the underlined bases
indicate the codon that was introduced during the mutagenesis.
a Generation of mutant previously described (Ward et al., 2002).
b Generation of mutant previously described (Chioato et al, 2002).
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addition of 5 mM Triton X-100. The effect of each mutant was measured in 6
independent experiments, and the data were analyzed using ANOVA with a
subsequent Tukey test.
2.5. Bactericidal activity
The bactericidal effect of BthTx-I and mutants was evaluated against the
Gram-negative bacteria E. coli (K12). Five mL of LB bacterial growth medium
was inoculated with a freshly grown colony and incubated for 12 h with
agitation at 37 °C. One mL of this culture was used to inoculate 50 mL of fresh
LB, and the culture was grown at 37 °C to an OD660 of 0.7. The bacteria were
diluted to a cell density of 4.5×106 cells mL−1 with sodium phosphate buffer,
pH 7.6 containing 1% tryptone. One hundred μL of this cell suspension were
incubated with BthTx-I and mutants at a final concentration of 3 μg mL−1 for 2 h
at 37 °C, and plated on solid LB medium. After incubation at 37 °C for 12 h, the
number of colony forming units was counted. The percentage inhibition of
colony forming units was calculated relative to the number of colonies present in
the negative control, which consisted of bacterial incubation with buffer alone.
The effect of each mutant was measured in 4 independent experiments, and the
data were analyzed using ANOVA with a subsequent Tukey test.
2.6. Myotoxic activity
The plasma creatine kinase (CK) activity was determined using the CK-UV
kinetic kit (Sigma Chemical Co.) after injection of 30 μg of BthTx-I in a totalvolume of 50 μL of PBS into the gastrocnemius muscle of male Swiss mice (wt
18–22 g) as previously described [35,38]. CK activity was expressed in U L−1,
where one unit is defined as the amount of enzyme that produces 1 mMol of
NADH min−1 under the standard conditions used in the assay. Animals used as
negative controls received 50 μL of PBS, and the CK activity data were analyzed
using ANOVAwith a subsequent Tukey test from a minimum of 4 independent
experiments.
2.7. Cytotoxic activity against C2C12 myoblasts
Mouse myogenic cells C2C12 (American Type Culture Collection;
Manassas, VA) were cultured as exponentially growing myoblasts at 37 °C in
a 5% CO2–95% air humidified atmosphere in a supplemented Dulbecco's
modified Eagle'smedium (DMEM) growthmedium containing 10% fetal bovine
serum (FBS), 4 mM L-glutamine and 100 UI mL−1 penicillin and 100 mg mL−1
streptomycin. Cells were harvested from subconfluent monolayers after
detachment by exposure to a trypsin solution (1500 U ml−1) containing
5.3 mMEDTA, for 5 min at 37 °C. The resuspended cells were seeded in 96-well
microplates, at an approximate initial density of between 1 to 4×104 cells per
well, in the same growthmedium.After reaching approximately 75%confluence,
undifferentiated myoblasts were utilized directly in the cytotoxicity assay. In this
assay, the cells were washed once with RPMI without phenol red and then
incubated with RPMI without phenol red +10 μM Sytox Green (Molecular
Probes, Oregon, USA) at 37 °C for 15 min. The cytotoxicity assay was initiated
by the addition of BthTx-I or mutant protein to each well at a final concentration
of 50 μg mL−1. Permeabilization of the cell membrane was monitored by the
increase in the fluorescence signal using a Gemini EM microplate spectro-
fluorometer (Molecular Devices, Sunnyvale, CA, USA) using 485 nm excitation
and 538 nm emission filters respectively. The fluorescence signal recorded after
30 min incubation was normalized to that measured after complete permeabiliza-
tion of the cells after the addition of 0.5%Triton X-100. The effect of eachmutant
was measured in the minimum in 6 independent experiments, and the data were
analyzed using ANOVAwith a subsequent Tukey test.
3. Results
Dideoxynucleotide sequencing of all coding sequences of
the BthTx-I revealed that the differences observed between the
native DNA nucleotide sequences and their respective mutants
(see Table 1) were only those introduced during the mutagen-
esis procedure. After expression and purification of the
heterologous BthTx-I and all mutants, SDS-PAGE of the re-
combinant protein showed the presence of a single band of
the correct molecular weight on silver staining (results not
shown). Furthermore, the farUVCD spectra of all mutant pro-
teins presented a spectral profile that was similar to the native
BthTx-I purified from the venom of B. jararacussu (results
not shown). These results demonstrate that the refolding and
purification protocols yielded protein with native-like second-
ary structure, and are similar to those previously reported for
the expression and purification of the recombinant BthTx-I
[35,36,38,43,46].
Fig. 1A shows the effects of the mutagenesis on the myotoxic
activity of the BthTx-I. The results demonstrate that the C-
terminal loop region of the protein is a structural determinant of
the activity, and that with the exception of residues 120 and 121,
residues at positions 117 to 125 are key determinants of this
effect together with position 37. The effect on myotoxic activity
is also dependent on of the type of amino acid substitution.
Whereas the introduction of alanine at positions 117, 119 and
125 reduces the myotoxic activity, the conservative substitution
by tryptophan has no effect demonstrating that aromatic
Fig. 1. (A) Myotoxicity assay comparing the native and mutants BthTx-I. Plasma creatine kinase (CK) activity was determined 3 h after injection of 30 μg native or
mutant BthTx-I into the mouse gastrocnemius muscle. See Materials and methods for experimental details. The results show the mean±s.d. of 4–12 independent
assays, and those mutants indicated by an asterisk (*) present an altered activity at a significance level of p<0.05. (B) Solid surface representations of the BthTx-I
monomer in three orientations showing the location of the mutations that significantly alter (p<0.05) the myotoxic activity. Ribbon representations (C) of the same
three orientations of the BthTx-I are included as a guide, and show (i) the view towards the C-terminal loop (in red), (ii) the view towards the interfacial binding site
(IRS) resulting from a 90 ° rotation around a vertical axis and (iii) the view towards the β-wing (in yellow) resulting from an additional 90° rotation. (For interpretation
of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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activity. Fig. 1B shows the localization of the residues that
significantly alter the myotoxic activity as shaded regions on a
solid surface representation of the BthTx-I molecule. The three
orientations shown in Fig. 1C present the view from (i) the C-terminal loop, (ii) the interfacial recognition site and (iii) the
beta wing. These figures demonstrate that the residues that are
the structural determinants of the myotoxic activity are all
located in a single surface cluster centered on the C-terminal
loop region.
1251L. Chioato et al. / Biochimica et Biophysica Acta 1768 (2007) 1247–1257The effects of the BthTx-I and site-directed mutants on the
permeabilization of cultured C2C12 myoblasts are presented
in Fig. 2. Fig. 2A shows that (with the exception of residues
120 and 121) the C-terminal region between residues 115 and
125 is a structural determinant of the membrane permeabi-
lization, along with residues 37 and 38. As is the case with
the in vivo myotoxic activity, conservative mutation of the
aromatic residues has no significant effect on the membrane
permeabilizing activity against myoblasts. Fig. 2B shows the
solid surface representation of these results, which when
compared to Fig. 1B, shows that there is a strong correlation
between the structural determinants of the activity against
myoblasts and the structural determinants of the myotoxic
effect. This result suggests that the underlying mechanisms ofFig. 2. (A) Membrane permeabilization of C2C12 myoblasts comparing the native an
the addition of native BthTx-I and mutants to C2C12 cell cultures at a final concentra
in which those mutants indicated by an asterisk (*) present an altered activity at a
monomer in three orientations showing the location of the mutations that significan
shown are the same as described in the legend to Fig. 1.membrane damage in myoblasts and the myotoxic activities
are correlated.
Fig. 3 shows the effect of mutagenesis on the bactericidal
activity of the BthTx-I, which reveals that mutation of all
residues in the C-terminal loop between positions 115 and 125
together with mutation of positions 7, 86 and 100 reduce the
effect of the toxin. It is noteworthy that this activity is not
affected by mutations around position 37, and furthermore that
conservative mutations of the aromatic residues in the C-
terminal region have similar effects on the reduction of the
bactericidal activity as the non-conservative mutations at these
positions. These differences are readily visualized in the solid
surface representations shown in Fig. 3B, which demonstrates
that the regions of the protein surface which acts as thed mutants BthTx-I. Increase in the Sytox Green fluorescence signal 30 min after
tion of 50 μg mL−1. The results show the mean±s.d. of 6–9 independent assays,
significance level of p<0.05. (B) Solid surface representations of the BthTx-I
tly alter (p<0.05) the membrane permeabilizing activity. The three orientations
Fig. 3. (A) Bactericidal activity of BthTx-I native and mutants on Escherichia coli K12. Proteins at a final concentration of 3 μg mL−1 were incubated with 4×105 E.
coli cells for 2 h at 37 °C. Surviving bacteria were counted by the dilution plate technique. The results show the mean±s.d. of 4 independent assays, in which those
mutants indicated by an asterisk (*) present an altered activity at a significance level of p<0.05. (B) Solid surface representations of the BthTx-I monomer in three
orientations showing the location of the mutations that significantly alter (p<0.05) the bactericidal activity. The three orientations shown are the same as described in
the legend to Fig. 1.
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overlap with the structural determinants of the myotoxic and
myoblast membrane permeabilizing activities.
Fig. 4 presents the effects of mutagenesis on the marker
release from liposomes composed of the phospholipid mixture
EYPC/DPPG at molar ratio of 9:1. These data show that
mutation of residues in the C-terminal loop region between
positions 115–127, together with residues in the region 36–43
and positions 46 and 53, all reduce the membrane damaging
activity of the BthTx-I. The representation of these results
shown in Fig. 4B reveals that the determinants of the liposome
membrane damaging activity present an extended surface that
includes most of the residues at the C-terminal extremity of
the molecule. Fig. 5 shows that most of the positions that
define the structural determinants of the membrane damaging
activity against EYPC/DPPG liposomes are also determinantsof the membrane of damaging activity against liposomes
composed of a EYPC/DMPA phospholipid mixture at a molar
ratio of 9:1.
A comparison of Figs. 4B and 5B indicates that the residues
around the C-terminal region appear to contribute to a
conserved surface that determines the activity against both
types of artificial membrane. Despite the similarities in the
pattern of the structural determinants of the membrane
damaging activity against the EYPC/DMPA and EYPC/DPPG
liposomes, several differences may be observed. In addition to
the extended surface at the C-terminal region that includes
residues 115–125 and 36–43 the mutations that decrease the
membrane damaging activity against the EYPC/DPMA lipo-
some membrane also include residues 7, 15, 53, 54, 80 and 100.
These additional positions show that the surface that acts as the
structural determinant of the membrane damaging activity
Fig. 4. (A) Calcium independent damaging activity of the native and mutant BthTx-I against EYPC:DPPG liposomes. Release of entrapped calcein from liposomes
(EYPC:DPPG at a 9:1 molar ratio) 150 s after mixing with 3 μg/mL of protein (at a final protein:lipid ratio of 1:400). The results show mean percentage±s.d. of 6
independent measurements, in which those mutants indicated by an asterisk (*) present an altered activity at a significance level of p<0.05. The data are normalized to
the release observed after addition of 5 mM Triton X-100. (B) Solid surface representations of the BthTx-I monomer in three orientations showing the location of the
mutations that significantly alter (p<0.05) the Ca2+ independent membrane damaging activity. The three orientations shown are the same as described in the legend to
Fig. 1.
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distributed across the IRS region of the protein. In addition to
this more extensive surface, conservative mutation of the
aromatic residues at positions 117 and 125 cause a respective
increase and decrease in the membrane damaging effect against
the EYPC/DMPA liposomes.
4. Discussion
The scanning alanine mutagenesis strategy has enabled us to
map of the structural determinants of various activities of the
BthTx-I. Previous results of site-directed mutagenesis studies of
9 residues in the C-terminal loop region of the protein
demonstrated that the residues at positions 118,119 and 122
are determinants of the myotoxic activity [38], and here we have
expanded this study to include 23 additional mutations atpositions distributed over the IRS of the protein. In addition to
the previously known positions, this study has demonstrated
that the additional structural determinants of myotoxicity are all
limited to a single cluster of residues centered on the C-terminal
loop, and includes residues around position 37. Furthermore,
the importance of the aromatic nature of the residue at position
125 has been established, which extends the region of the C-
terminal loop that contributes to the myotoxic site. Comparison
of the residues that were identified in the present study with a
list of positions previously predicted to be determinants of the
myotoxic activity by the residue variability analysis of the
Lys49–PLA2s [5], confirms that 4 of the 8 predicted residues
are located in the surface cluster that determines the myotoxic
activity.
The results of the present study show a striking coherence
with previous reports of the myotoxic and bactericidal effects
Fig. 5. (A) Calcium independent damaging activity of the native and mutant BthTx-I against EYPC:DMPA liposomes. Release of entrapped calcein from liposomes
(EYPC:DMPA at a 9:1 molar ratio) 150 s after mixing with 3 μg/mL of protein (at a final protein:lipid ratio of 1:400). The results show mean percentage±s.d. of 6
independent measurements, in which those mutants indicated by an asterisk (*) present an altered activity at a significance level of p<0.05. The data are normalized to
the release observed after addition of 5 mM Triton X-100. (B) Solid surface representations of the BthTx-I monomer in three orientations showing the location of the
mutations that significantly alter (p<0.05) the Ca2+-independent membrane damaging activity. The three orientations shown are the same as described in the legend to
Fig. 1.
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C-terminal regions of myotoxin II from B. asper (BaspMT-II,
[15,25]) and other Lys49–PLA2s [47–50]. The C-terminal
peptide from BaspMT-II shares 85% identity with the homo-
logous region in the C-terminus of BthTx-I, and although this
peptide reproduces the effects observed in the C-terminal
mutants of the BthTx-I, the concentration of the peptide needed
to elicit a given effect is approximately 100-fold higher than that
for the intact protein. The higher activity of the full protein may
be due to the contribution by the other regions in addition to the
C-terminal region that have been identified in this study.
Furthermore, the C-terminal loop region is tethered to the body
of the protein by two disulphide bridges, and the absence of
these restraints in the synthetic peptide is likely to result inhigher entropy of the peptide and consequently a reduced
stability of the active conformation.
This report includes the first systematic study by site-
directed mutagenesis of the bactericidal activity of a Lys49–
PLA2, which demonstrates that the structural determinants of
the bactericidal effect are more extensive and only partially
superposed with those of the C2C12 cell membrane damaging
and myotoxic activities. Comparison of the influence of
mutagenesis on the bactericidal effect and liposome membrane
damage reveals that although the C-terminal region of the
protein is a structural determinant of both activities, other
regions of the protein are also involved. The mutation K7A
resulted in a significant reduction in both the bactericidal
activity and the Ca2+-independent activity against membranes
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previous reports, in which acetylation or cleavage of the N
terminal octapeptide of the Lys49–PLA2 BNSP-7 inhibited the
bactericidal activity against E. coli [26]. It is noteworthy that the
same mutations did not influence either the myotoxic activity or
the membrane permeabilization of C2C12 myoblasts, and is in
agreement with previous results which have demonstrated that
incubation with monoclonal antibodies against the N-terminal
region of the Lys49–PLA2s did not influence biological activity
[51]. These results emphasize that the composition of the target
membrane exerts a significant influence on the observed
activities of the BthTx-I. Although the results indicate sub-
stantial differences in the structural determinants of the
liposome membrane damaging effects in comparison to the
biological membranes, the experiments with model membranes
yield insights with respect to the membrane damaging me-
chanism that provide guidelines for the interpretation of the
results in the more complex biological systems.
The activity of all mutants was evaluated against liposome
membranes composed of both EYPC/DMPA and EYPC/DPPG.
Although the activity is higher against EYPC/DMPA mem-
branes and modulation of the effect of specific mutations is also
observed, the structural determinants of the damaging effect
against both membrane types are broadly similar (compare Figs.
4 and 5). These differences demonstrate that the roles of
individual amino acids may be modulated by the composition of
the target membrane, which in turn suggests that the activity of
the BthTx-I against a phospholipid membrane is mediated by
the overall physico-chemical properties of the IRS rather than
specific phospholipid binding sites. Mapping of the structural
determinants of the bactericidal effect reveals a distribution
more similar to that observed for the liposome membranes,
suggesting a non-specific lipid-mediated interaction with the
target membrane. In comparison, the close clustering of the
structural determinants of the myotoxic and myoblast mem-
brane permeabilization activities are suggestive of a more
specific interaction of the BthTx-I with these membranes,
perhaps mediated by a membrane associated acceptor.
Our results give a deeper understanding as to the structural
basis of the mechanism of the Lys49–PLA2s. Comparison of 18
crystal structures of Lys49–PLA2s from 8 Agkistrodon and
Bothrops species has shown that residues in the C-terminal
region have an enhanced flexibility [17], and that the binding of
amphiphilic molecules to the protein is generally correlated with
the exposure of conserved hydrophobic residues in the region
120–125 (the so-called hydrophobic knuckle) [17]. These
observations have led to the proposal that the binding of lipids
to the active site results in a conformation change of the C-
terminal loop exposing residues L121 and F125, and that this
altered surface hydrophobicity contributes to activation of the
membrane damaging activity of the protein [17]. This is
consistent with the previous suggestion that the hydrophobic
residues in the C-terminal region play a role in target membrane
permeabilization [47–50]. Furthermore, mutants of BthTx-I
with an altered topology of the substrate-binding site show a
reduced membrane damaging activity, providing supportive
evidence for a functional link between the substrate-bindingregion and residues in the C-terminal loop involved with the
Ca2+-independent liposome membrane damaging activity [36].
Here we have not only demonstrated that the region 122–125
is a structural determinant of all functions that were studied,
but also that the hydrophobicity of position 125 may influence
the activity of the protein. These results add support to the
proposal that conformation change in the C-terminal loop on
substrate binding contributes to the activation of the membrane
damaging activity of the Lys49–PLA2s.
On the basis of experiments using erythrocytes enriched with
phosphatidylserine and lipopolysaccharide from Gram-negative
bacteria, it has been suggested that the permeabilization of the
cell membranes by the Lys49–PLA2s is a key event in the
pathological mechanism [52]. The close correlation observed
between the structural determinants of the in vivo myotoxicity
and the membrane permeabilization effect against cultured
C2C12 myoblasts adds support to this idea. However, previous
reports have demonstrated that the myotoxic and artificial
membrane damaging activities may be separated [37,38]. The
absence of any effect of active site mutants on the myotoxic
activity suggests either that the conformation of this region is
conserved on activation of the membrane damaging activity on
membrane binding, or that any change that is induced has no
effect on the myotoxic activity of the protein. This implies that
the previously observed separation of the myotoxic and
membrane permeabilizing [37,38] is a consequence of differ-
ences in the mechanism of binding and activation of the
membrane damaging effects against muscle and liposome
membranes. We propose that on interaction with liposome
membranes containing anionic lipids, the direct lipid binding to
the active site activates the BthTx-I and under these circum-
stances the binding and activation are concomitant events. This
compares to the binding of the toxin to muscle cell membranes
where the membrane binding and protein activation are
separated. This explains why the knuckle region appears as a
determinant in all assays, since the interaction of hydrophobic
surface patch is a conserved feature of the activity against all
membranes. However, in the case of the myotoxic and myoblast
activities the activation event is separated from the lipid
binding, and is triggered by additional events occurring after
association with the membrane. Previous results have clearly
separated the binding of Lys49–PLA2 to the target membrane
from the cytotoxic effects of the protein [49], suggesting that
the events after membrane binding are responsible for the
manifestation of cytotoxic effects of the protein. The results of
this study lead us to conclude that membrane-binding motifs are
important for myotoxic and membrane damaging activities,
however the underlying mechanism of activation on muscle cell
membranes is different from that on bacterial membranes and
liposomes.
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